By K. David Epley, MD
The contents of this article are informational only and are not intended to be a substitute for professional medical advice, diagnosis, or treatment recommendations. This editorial presents the views and experiences of the author and does not reflect the opinions or recommendations of the publisher of Optometry 360.
Amblyopia affects approximately 3% of children, roughly 1 million children in the United States, making it one of the most common causes of vision loss in childhood.1 For pediatric ophthalmologists, it is not a rare condition encountered occasionally; it is a routine and clinically important part of practice. In my own clinic, amblyopia represents more than half of the children I see, most commonly between ages 2 and 10, with a smaller but still meaningful group of older children and adolescents who have residual disease.
Treating amblyopia
The urgency of treatment is rooted in neurodevelopment. Amblyopia occurs when the brain does not develop the visual wiring needed to process input clearly from 1 eye, most often because of unequal refractive error, strabismus, or obstruction of the visual pathway. It is not simply a focusing problem. A child can have the correct glasses prescription and still experience blurred or incomplete vision because the brain has not learned to use the visual signal normally.
The 3 core tools I most often discuss with families to treat amblyopia are Luminopia, patching, and atropine.
Luminopia is the latest option for the treatment of amblyopia and is changing the clinical conversation. It is an FDA-cleared prescription digital therapeutic indicated to improve visual acuity in children aged 4 to <13 years with amblyopia associated with anisometropia and/or mild strabismus. It uses a software-based approach delivered through a VR headset, allowing children to watch age-appropriate programming for an hour a day while the software modifies content to encourage use of both eyes together.
The binocular approach is important because amblyopia is not only about visual acuity. Binocular function, including depth perception and stereopsis, also matters. In my practice, I have seen children using Luminopia improve their visual acuity while also making gains in stereo vision, which is clinically meaningful when thinking about the broader goals of treatment.
For decades, eye patching has been a mainstay of amblyopia care. There is no question that patching works when children do it. I patched as a child myself, and I remain grateful that option existed, that my doctor prescribed it, and that my parents enforced it. I still prescribe patches today, and they remain one of the most accessible tools available to families.
However, patching has practical limitations and patient compliance issues. It works by occluding the stronger eye and forcing the child to use the weaker eye. That can be uncomfortable and frustrating because the child is being asked to function while relying on the eye that does not see well. Patches can be hot, sweaty, and socially difficult. Children may peek around them, peel up the edges, or resist wearing them altogether. They are not being difficult; it is because they want to see better.
There is also a psychosocial component. Parents often report that children do not want to wear a patch at school because of embarrassment or teasing. School hours can account for valuable patching time because children are using their vision intensively, but many families end up trying to complete patching outside of school, when they are already managing homework, sports, dinner, and bedtime.
Atropine is another useful treatment option, particularly for younger children who simply will not keep a patch on. Once the drop is administered into the eye, it is not easily “cheated,” and it can be effective for penalization.
Finally, the efficacy of traditional amblyopia treatments has generally been understood to decline with age, as neuroplasticity in the visual system is believed to lessen beginning around age 8. Recent Luminopia data challenge that longstanding assumption, with data demonstrating that Luminopia provides equivalent efficacy in both younger and older children, a first in the treatment of amblyopia.2
The treatment decision should be individualized. Infants and very young children may be better suited for patching or atropine because they are not candidates for a VR headset. For school-age children, I often present all 3 options and discuss what the family can realistically implement based on lifestyle. Parents frequently ask which treatment is most effective. My answer is that the most effective treatment is the one they can actually complete at home.
Luminopia data
Luminopia is clinically interesting because it offers a treatment experience that many children are motivated to participate in. For some patients, the ability to watch programming through a VR headset can make the difference between a therapy that is prescribed and a therapy that is actually completed.
The data supporting Luminopia have also continued to mature. In the pivotal randomized, controlled trial, children treated with Luminopia plus refractive correction improved an average of 1.8 lines in best-corrected visual acuity (BCVA) at 12 weeks compared with 0.8 lines in the control group receiving refractive correction alone.3 Luminopia has also been evaluated through the PUPiL Registry, which provides real-world data across a broader clinical population.
Recent peer-reviewed publications help address an important question for clinicians: does performance in a controlled trial translate into routine real-world practice? In a recently published Journal of Managed Care & Specialty Pharmacy analysis looking at registry patients with similar characteristics to patients from the pivotal trial, children treated in real-world practice achieved visual acuity improvements consistent with the randomized clinical trial. Registry patients improved an average of 1.7 lines at 12 weeks compared with 1.8 lines in the trial treatment group, with no adverse events reported among the registry cohort analyzed.4
Durability of vision gains is also relevant. A BMC Ophthalmology analysis of children who completed Luminopia treatment in the PUPiL Registry found a mean 1.4-line improvement in BCVA after an average treatment duration of approximately 7 months. Visual gains were maintained after treatment discontinuation, with amblyopia recurrence reported in only 3% of patients.5
For physicians, real-world data matter because our patients rarely fit neatly into clinical trial criteria. We need to understand whether a treatment is feasible, tolerated, and effective in the context of actual family life. Luminopia also provides objective usage data through a provider portal, which can help clinicians better understand adherence. With patching and drops, we are often relying on parent or patient reports, which may not always reflect the actual treatment completed.
Additionally, cost and insurance coverage can also affect access to treatment options, and those considerations should remain part of shared decision-making with the family. Fortunately, the number of insurance companies that cover Luminopia is growing.
Still, the value of innovation in amblyopia care is not that it replaces every existing tool. Its value is that it expands the treatment toolbox. Some children will do well with patching. Others may be better suited for atropine. Others may benefit from a binocular, engaging treatment that fits more naturally into daily life.
Amblyopia treatment has always required persistence from clinicians, parents, and children. The more evidence-based options we have, the better positioned we are to match treatment to the patient, and the better chance we have of improving vision while the opportunity to intervene remains.
K. David Epley, MD, practices comprehensive pediatric ophthalmology at Children’s Eye Care, a private practice in Kirkland, Washington. Disclosures: Dr. Epley is a consultant to Luminopia.
References
- Amblyopia (Lazy Eye). National Institutes of Health. Updated March 15, 2024. Accessed August 27, 2026. https://www.nei.nih.gov/eye-health-information/eye-conditions-and-diseases/amblyopia-lazy-eye
- Bohnsack BL, Ghasia F, Hancock S, Warner N, Gaier ED. Real world gains stable in children with amblyopia following digital dichoptic treatment: PUPiL registry results. BMC Ophthalmology. 2026;26:217. doi:10.1186/s12886-026-04747-3
- Xiao S, Angjeli E, Wu HC, et al. Luminopia pivotal trial group. Randomized controlled trial of a dichoptic digital therapeutic for amblyopia. Ophthalmology. 2022;129(1):77-85. doi:10.1016/j.ophtha.2021.09.001
- Gaier ED, Bohnsack BL, Bodack MI, et al. Equivalent effectiveness of a prescription binocular treatment for amblyopia in real-world practice. J Manag Care Spec Pharm. 2026;32(7):1-9. doi:10.18553/jmcp.2026.25336
- Bohnsack BL, Bodack MI, Binenbaum G, et al. Real world gains stable in children with amblyopia following digital dichoptic treatment: PUPiL registry results. BMC Ophthalmology. 2026;26:217. doi:10.1186/s12886-026-04747-3
Related Content
